Pyroptosis‐related gene GSDMC indicates poor prognosis and promotes tumor progression by activating the AKT/mTOR pathway in lung squamous cell carcinoma
Molecular Carcinogenesis · 2024
DOI: 10.1002/mc.23805 ↗At a glance
Journal article in Molecular Carcinogenesis, 2024. Written by Yi Zhang and 10 co-authors. Institution: Shengli Clinical Medical College, Fujian Medical University, Fuzhou, Fujian, China. Major MEDLINE topics: TOR Serine-Threonine Kinases, Lung Neoplasms, Proto-Oncogene Proteins c-akt, Pyroptosis. Cited 4 times so far (Crossref); 67 references. Funded by: Medical Vertical Project of Fujian Province, Key Project of Natural Science Foundation of Fujian province, Joint fund of science and technology innovation of Fujian province.
Abstract (original language)
Lung squamous cell carcinoma (LUSC) is one of the most common malignant tumors of the respiratory. Pyroptosis plays an essential role in cancer, but there is limited research investigating pyroptosis in LUSC. In this study, pyroptosis‐related genes were observed to have extensive multiomics alterations in LUSC through analysis of the TCGA database. Utilizing machine learning for selection and verifying expression levels, GSDMC was chosen as the critical gene for further experiments. Our research found that GSDMC is overexpressed in LUSC tissues and cells, and is associated with poor prognosis. Knockdown of GSDMC in LUSC inhibits cell proliferation, invasion, metastasis, chemotherapeutic sensitivity, and reduced tumor formation in nude mice, accompanied by downregulation of proliferative and EMT‐related protein expression. However, these effects were counteracted in cells where GSDMC is overexpressed. Mechanistically, the oncogenic role of GSDMC is primarily achieved through the activation of the AKT/mTOR pathway, and this effect can be significantly reversed by rapamycin. Finally, SMAD4's interaction with the promoter region of GSDMC results in the suppression of GSDMC expression. In summary, our study through bioinformatics and experimental approaches not only proves that SMAD4 regulates the protumorigenic role of GSDMC through transcriptional targeting, but also indicates the possibility of developing the SMAD4/GSDMC/AKT/mTOR signaling axis as a potential biomarker and treatment target for LUSC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Shengli Clinical Medical College, Fujian Medical University, Fuzhou, Fujian, China.
- Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, Fujian, China.
- Department of Laboratory Medicine, Deyang People's Hospital, Deyang, Sichuan, China.
- Integrated Chinese and Western Medicine College, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
- Department of General Thoracic Surgery, Fujian Provincial Hospital, Fujian Medical University, Fuzhou, Fujian, China.
- Department of Scientific Research, Fujian Provincial Hospital, Fuzhou, Fujian, China.
Funding
- Medical Vertical Project of Fujian Province
- Key Project of Natural Science Foundation of Fujian province
- Joint fund of science and technology innovation of Fujian province
Cite
APA
Zhang, Y., Wang, Y., Weng, J., Chen, J., Zheng, Y., Xia, Y., Huang, Z., Zhao, L., Chen, X., Tang, H., & Huang, Y. (2024). Pyroptosis‐related gene GSDMC indicates poor prognosis and promotes tumor progression by activating the AKT/mTOR pathway in lung squamous cell carcinoma. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23805
Vancouver
Zhang Y, Wang Y, Weng J, Chen J, Zheng Y, Xia Y, et al. Pyroptosis‐related gene GSDMC indicates poor prognosis and promotes tumor progression by activating the AKT/mTOR pathway in lung squamous cell carcinoma. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23805
BibTeX
@article{Zhang2024,
author = {Zhang, Yi and Wang, Yuzhi and Weng, Jiamiao and Chen, Jianlin and Zheng, Yue and Xia, Yu and Huang, Zhixin and Zhao, Lilan and Chen, Xiongfeng and Tang, Haijun and Huang, Yi},
title = {Pyroptosis‐related gene GSDMC indicates poor prognosis and promotes tumor progression by activating the AKT/mTOR pathway in lung squamous cell carcinoma},
journal = {Molecular Carcinogenesis},
year = {2024},
doi = {10.1002/mc.23805}
}
EUVIMED